UBE4B and neuroblastoma: To determine the primary pathway of UBE4B and STUB1-mediated Tau degradation, we co-overexpressed UBE4B and STUB1 with Tau in neuroblastoma cells, and treated the cells with either the UPS inhibitor MG132 or the ALS inhibitors.